分析利拉鲁肽联合达格列净治疗肥胖2型糖尿病患者的临床有效性  

Clinical Efficacy of Liraglutide Combined with Dapagliflozin in the Treat⁃ment of Obese Patients with Type 2 Diabetes Mellitus

作　　者：张璐[1] 孙凌雁 姚晨 ZHANG Lu;SUN Lingyan;YAO Chen(Department of Pharmacy,Yantai Mountain Hospital,Yantai 264001,Shandong,China)

机构地区：[1]烟台市烟台山医院药剂科,山东烟台264001

出　　处：《糖尿病新世界》2024年第12期67-69,81,共4页Diabetes New World

摘　　要：目的分析利拉鲁肽+达格列净治疗肥胖2型糖尿病(type 2 diabetes mellitus,T2DM)患者的效果。方法选取2023年1—12月烟台市烟台山医院收治的68例肥胖T2DM患者为研究对象,按治疗方法不同分为对照组、观察组,各34例,对照组实施单纯利拉鲁肽治疗,观察组实施利拉鲁肽联合达格列净治疗,比较两组肥胖指标[体重指数(body mass index,BMI)、腰围]、血糖指标(空腹血糖、餐后2 h血糖和糖化血红蛋白)、血脂指标(甘油三酯、总胆固醇、低密度脂蛋白胆固醇及高密度脂蛋白胆固醇)、不良反应。结果治疗后,观察组BMI、腰围、血糖指标均低于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组各项血脂指标均优于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论利拉鲁肽+达格列净治疗肥胖T2DM可改善肥胖,并降低血糖,改善血脂,不良反应少,使用安全。Objective To investigate the efficacy of liraglutide plus dapagliflozin in the treatment of obese patients with type 2 diabetes mellitus(T2DM).Methods A total of 68 T2DM obese patients admitted to Yantais Mountain Hos-pital of Yantai City from January to December 2023 were selected as the research objects.According to different treat-ment methods,they were divided into control group and observation group,with 34 cases in each group.The control group was treated with liraglutide alone,and the observation group was treated with liraglutide combined with dapa-gliflozin.The obesity indexes[body mass index(BMI),waist circumference],blood glucose indexes(fasting blood glu-cose,2-hour postprandial blood glucose and glycated hemoglobin A1c),blood lipid indexes(triglyceride,total choles-terol,low density lipoprotein cholesterol and high density lipoprotein cholesterol)and adverse reactions were compared between the two groups.Results After treatment,BMI,waist circumference and blood glucose indexes in observation group were lower than those in control group,and the differences were statistically significant(all P<0.05).After treat-ment,the blood lipid indexes in the observation group were better than those in the control group,and the differences were statistically significant(all P<0.05).Compared the incidence of adverse reactions in both groups,and the differ-ence was not statistically significant(P>0.05).Conclusion Liraglutide+dapagliflozin treatment for obese T2DM can im-prove obesity,reduce blood glucose,improve blood lipids,have fewer adverse reactions,and is safe to use.

关 键 词：利拉鲁肽 达格列净 肥胖 2型糖尿病 血糖 

分 类 号：R4[医药卫生—临床医学]